AJMB  Vol.7 No.4 , October 2017
Wolman Disease in Bulgarian Patients: Selective Genetic Screening in Two Presumable Endemic Regions
Wolman disease is a rare autosomal recessive disorder caused by mutations in the LIPA gene (10q23.31). The LIPA gene encodes lysosomal acid lipase (LAL), which plays a key role in hydrolysis of the cholesteryl esters and triglycerides. Two unrelated families from Bulgaria were referred for genetic testing with clinical diagnosis Wolman disease. Sanger sequencing of all coding exons and exon-intron boundaries of the LIPA gene was performed. The index patients were found to be homozygous for two different mutations in the LIPA gene: a missense mutation, c.260G > T, p.Gly87Val, which affects the enzyme active site and a splice-site change, c.822+1G > A, which most probably destroys the enzyme polypeptide chain. These two completely different types of mutations along the LIPA gene resulted in a very similar phenotype involving liver, kidney, gastrointestinal, muscle and blood disturbances. As consanguinity is not typical for the Bulgarian population, a possible explanation of the homozygosity could be presence of endemic regions for given mutations. To check this hypothesis, selective screening for these mutations was performed in two presumable endemic regions in Bulgaria. Altogether, 100 newborns were screened for p.Gly87Val mutation and the detected carrier frequency was about 1% (1/100), while in the group of 100 newborns screened for the c.822 + 1G > A mutation the detected carrier frequency was 2% (2/100). The results indicate a high recurrence risk of Wolman disease in these particular Bulgarian regions of about 1:10000. These findings are from crucial importance for the inhabitants of the corresponding parts of Bulgaria. They may benefit from early genetic testing and adequate genetic counselling during family planning.
Cite this paper
Mandadzhieva, A. , Avdzhieva-Tzavella, D. , Todorov, T. , Tincheva, S. , Sinigerska, V. , Ivanova, M. , Savov, A. , Mitev, V. and Todorova, A. (2017) Wolman Disease in Bulgarian Patients: Selective Genetic Screening in Two Presumable Endemic Regions. American Journal of Molecular Biology, 7, 169-175. doi: 10.4236/ajmb.2017.74013.
[1]   Zschenker, O., Jung, N., Rethmeier, J., Trautwein, S., Hertel, S., Zeigler, M. and Ameis, D. (2001) Characterization of Lysosomal Acid Lipase Mutations in the Signal Peptide and Mature Polypeptide Region Causing Wolman Disease. Journal of Lipid Research, 42, 1033-1040.

[2]   Aslanidis, C., Klima, H., Jackner, K. and Schmitz, G. (1994) Genomic Organization of the Human Lysosomal Acid Lipase Gene (LIPA). Genomics, 20, 329-331.

[3]   Aslanidis, C., Ries, S., Fehringer, P., Buchler, C., Klima, H. and Schmitz, G. (1996) Genetic and Biochemical Evidence That CESD and Wolman Disease Are Distinguished by Residual Lysosomal Acid Lipase Activity. Genomics, 33, 85-93.

[4]   Reiner, Z., Guardamagna, O., Nair, D., Soran, H., Hovingh, K., Bertolini, S., Jones, S., Coric, M., Calandra, S., Hamilton, J., Eagleton, T. and Ros, E. (2014) Lysosomal Acid Lipase Deficiency—An under Recognized Cause of Dyslipidaemia and Liver Dysfunction. Atherosclerosis, 235, 21-30.

[5]   Xu, M., Motabar, O., Ferrer, M., Marugan, J., Zheng, W. and Ottinger, E. (2016) Disease Models for the Development of Therapies for Lysosomal Storage Diseases. Annals of the New York Academy of Sciences 2016, 1371, 15-29.

[6]   Aguisanda, F., Thorne, N. and Zheng, W. (2017) Targeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development. Current Chemical Genomics and Translational Medicine, 11, 1-18.

[7]   Tolar, J., Petryk, A., Khan, K., Bjoraker, K.J., Jessurun, J., Dolan, M., Kivisto, T., Charnas, L., Shapiro, E.G. and Orchard, P.J. (2008) Long-Term Metabolic, Endocrine, and Neuropsychological Outcome of Hematopoietic Cell Transplantation for Wolman Disease. Bone Marrow Transplant, 43, 21-27.

[8]   Krivit, W., Peters, C., Dusenbery, K., Ben-Yoseph, Y., Ramsay, N.K., Wagner, J.E. and Anderson, R. (2000) Wolman Disease Successfully Treated by Bone Marrow Transplantation. Bone Marrow Transplant, 26, 567-570.

[9]   Barton, N.W., Brady, R.O., Dambrosia, J.M., Di Bisceglie, A.M., Doppelt, S.H., Hill, S.C., Mankin, H.J., Murray, G.J., Parker, R.I., Argoff, C.E., et al. (1991) Replacement Therapy for Inherited Enzyme Deficiencymacrophage-Targeted Glucocerebrosidase for Gauchers Disease. New England Journal of Medicine, 324, 1464-1470.

[10]   Braulke, T. and Bonifacino, J. (2009) Sorting of Lysosomal Proteins. Biochimica et Biophysica Acta, 1793, 605-614.

[11]   Todorova, A., Ashikov, A., Beltcheva, O., Tournev, I. and Kremensky, I. (1999) C283Y Mutation and Other C-Terminal Nucleotide Changes in the G-Sarcoglycan Gene in the Bulgarian Gypsy Population. Human Mutation, 14, 40-44.

[12]   Pagani, F., Garcia, R., Pariyarath, R., Stuani, C., Gridelli, B., Paone, G. and Baralle, F. (1996) Espression of Lysosomal Acid Lipase Mutants Detected in Three Patients with Cholesteryl Ester Storage Disease. Human Molecular Genetics, 1611-1617.

[13]   Pagani, F., Pariyarath, R., Garcia, R., Stuani, C., Burlina, A., Ruotolo, G., Rabusin, M. and Baralle, F. (1998) New Lysosomal Acid Lipase Gene Mutants Explain the Phenotype of Wolman Disease and Cholesteryl Ester Storage Disease. Journal of Lipid Research, 39, 1382-1388.

[14]   Valles-Ayoub, Y., Esfandiarifard, S., Sinai, P., Khokher, Z., Kohan, M., Kahen, T. and Darvish, D. (2011) Wolman Disease (LIPA p.G87V) Genotype Frequency in People of Iranian-Jewish Ancestry. Genetic Testing and Molecular Biomarkers, 15, 395-398. https://doi.org/10.1089/gtmb.2010.0203

[15]   https://www.ncbi.nlm.nih.gov/clinvar/variation/88770/

[16]   Yang, Y., Fernandes, P.H., Miloslavskaya, I., Orchard, P., Schwarzenberg, S.J., Grimley, M., O’Brien, W.E. and Eng, C.M. (2009) Molecular Diagnosis of Wolman/CESD Disease: Mutation Detection and Genotype-Phenotype Correlations.

[17]   Griffiths, A.J.F. (1999) The Molecular Basis of Mutation. Modern Genetic Analysis. New York.

[18]   Todorova, A. and Danieli, G.A. (1997) Large Majority of Single-Nucleotide Mutations along the Dystrophin Gene Can Be Explained by More than One Mechanism of Mutagenesis. Human Mutation, 9, 537-547.

[19]   Li, W.-H., Wu, C.-I. and Luo, C.-C. (1984) Non-Randomness of Point Mutation as Reflected in Nucleotide Substitutions in Pseudogenes and Its Evolutionary Implications. Journal of Molecular Evolution, 27, 58-71.

[20]   Vogel, F. (1972) Non-Randomness of Base Replacement in Point Mutation. Journal of Molecular Evolution, 1, 334-367.